Effect of Vitamin D3 Supplementation on Symptomatic Uterine Fibroid in Women With Vitamin D Deficiency

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY

39 women with symptomatic uterine fibroid with serum vitamin D deficiency will receive vitamin D3 supplementation for 6 month.then symptoms and size of fibroid will be re evaluated..

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 50
Healthy Volunteers: f
View:

⁃ .Women aged between 18-50 not currently pregnant, lactating, or planning to conceive during the study period.

• Women with a confirmed diagnosis of uterine fibroids (leiomyoma) through ultrasound.

• Serum 25-hydroxyvitamin D \[25(OH)D\] levels below 20 ng/mL (indicating vitamin D deficiency).

• Presence of symptoms associated with uterine fibroid, such as menorrhagia (heavy menstrual bleeding), or bulk-related symptoms (e.g., urinary frequency).

• Participants should be generally healthy, with no history of other chronic illnesses that could affect the study's outcomes (e.g., autoimmune diseases, cancers, severe liver or kidney diseases).

• Willingness to provide written informed consent for participation in the study.

• No current use of hormonal therapy, other vitamin D supplements, or medications known to influence calcium metabolism or uterine fibroid growth (e.g., GnRH agonists, anti-estrogens).

• Participants must be willing and able to adhere to the study protocol, including attending follow-up visits and completing any required assessments or tests.

Locations
Other Locations
Bangladesh
Bangabandhu Sheikh Mujib medical university
RECRUITING
Dhaka
Bangabandhu Sheikh Mujib medical university
RECRUITING
Dhaka
Contact Information
Primary
Nahida Akter, MBBS
nahidamili16@gmail.com
+8801635576296
Time Frame
Start Date: 2025-02-20
Estimated Completion Date: 2026-09
Participants
Target number of participants: 39
Treatments
Experimental: Pt with uterine fibroid
Study subjects will be selected according to inclusion and exclusion criteria, consents will be taken in informed written consent form, and then preceded as follow- 39 diagnosed women with uterine fibroid aged 18 to 50 years experiencing heavy menstrual bleeding will be purposively selected upon meeting the selection criteria Demographic information, medical history, clinical examination findings, and other relevant clinical data will be gathered through interviews Baseline Assessments: menstrual blood loss, hemoglobin concentration and ultrasound parameters (uterine volume, fibroid characteristics) Participants received 25(OH) Vitamin D3 orally
Sponsors
Leads: Nahida Akter

This content was sourced from clinicaltrials.gov